

**Clinical trial results:****A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection****Summary**

EudraCT number	2017-002156-84
Trial protocol	SE LV LT FR DE SK BE CZ NL ES HU BG PL GB AT IT Outside
Global end of trial date	58/55A 28 May 2020

**Results information**

Result version number	v1 (current)
This version publication date	13 March 2021
First version publication date	13 March 2021

Summary attachment (see zip file)	63623872FLZ3001 (2017-002156-84)_Limited Results (63623872FLZ3001_Redacted CSR synopsis.pdf)
-----------------------------------	--

**Trial information****Trial identification**

Sponsor protocol code	63623872FLZ3001
-----------------------	-----------------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03376321
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920 Route 202, Raritan, United States, NJ 08869
Public contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001975-PIP01-16
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 May 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 May 2020
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The primary objective is to evaluate superiority of pimodivir in combination with standard-of-care (SOC) treatment compared to placebo in combination with SOC treatment on Day 6, with respect to the clinical outcome on the hospital recovery scale.

Protection of trial subjects:

Safety assessments included AE, laboratory parameters, electrocardiogram [ECG], vital signs, and National Early Warning Score [NEWS2]).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 December 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Netherlands: 3
Country: Number of subjects enrolled	Poland: 24
Country: Number of subjects enrolled	Slovakia: 1
Country: Number of subjects enrolled	Spain: 24
Country: Number of subjects enrolled	Sweden: 16
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Austria: 18
Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	Bulgaria: 10
Country: Number of subjects enrolled	France: 9
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Italy: 4
Country: Number of subjects enrolled	Latvia: 3
Country: Number of subjects enrolled	Lithuania: 4
Country: Number of subjects enrolled	Israel: 36
Country: Number of subjects enrolled	Brazil: 3
Country: Number of subjects enrolled	Vietnam: 1

Country: Number of subjects enrolled	United States: 36
Country: Number of subjects enrolled	Malaysia: 21
Country: Number of subjects enrolled	India: 18
Country: Number of subjects enrolled	Ukraine: 14
Country: Number of subjects enrolled	Russian Federation: 1
Country: Number of subjects enrolled	South Africa: 17
Country: Number of subjects enrolled	Australia: 2
Country: Number of subjects enrolled	Argentina: 9
Country: Number of subjects enrolled	Turkey: 8
Country: Number of subjects enrolled	Mexico: 12
Country: Number of subjects enrolled	Singapore: 2
Country: Number of subjects enrolled	Chile: 1
Country: Number of subjects enrolled	New Zealand: 1
Country: Number of subjects enrolled	Taiwan: 1
Country: Number of subjects enrolled	Thailand: 22
Worldwide total number of subjects	326
EEA total number of subjects	119

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	4
Adults (18-64 years)	192
From 65 to 84 years	130
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Overall, 334 subjects were randomized, of which 326 (97.6%) subjects were treated (and included in the Safety Set).

### Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Pimodivir + SOC

Arm description:

Subjects received pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for subjects who received only 1 dose of pimodivir on Day 1 [evening], dosing continued until the morning of Day 6) along with SOC treatment.

Arm type	Experimental
Investigational medicinal product name	Pimodivir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Pimodivir was administered.

<b>Arm title</b>	Placebo + SOC
------------------	---------------

Arm description:

Subjects received placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for subjects who received only 1 dose of placebo on Day 1 [evening], dosing continued until morning of Day 6) along with SOC treatment.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo was administered.

<b>Number of subjects in period 1</b>	Pimodivir + SOC	Placebo + SOC
Started	163	163
Completed	145	141
Not completed	18	22
Adverse event, serious fatal	4	-
Consent withdrawn by subject	8	14
Other	5	1
Lost to follow-up	1	7

## Baseline characteristics

## End points

### End points reporting groups

Reporting group title	Pimodivir + SOC
Reporting group description: Subjects received pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for subjects who received only 1 dose of pimodivir on Day 1 [evening], dosing continued until the morning of Day 6) along with SOC treatment.	
Reporting group title	Placebo + SOC
Reporting group description: Subjects received placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for subjects who received only 1 dose of placebo on Day 1 [evening], dosing continued until morning of Day 6) along with SOC treatment.	

### Primary: Hospital Recovery Scale on Day 6

End point title	Hospital Recovery Scale on Day 6
End point description: The hospital recovery scale assesses a participant's clinical status. The scale provides 6 mutually exclusive conditions ordered from best to worst: 1) not hospitalized; 2) non-ICU hospitalization, not requiring supplemental oxygen (SO); 3) non-ICU hospitalization, requiring supplemental oxygen; 4) admitted to the ICU, not requiring invasive mechanical ventilation (IMV); 5) requiring invasive mechanical ventilation; and 6) death.	
End point type	Primary
End point timeframe: Day 6	

End point values	Pimodivir + SOC	Placebo + SOC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	159	159		
Units: subjects				
Not hospitalized	73	69		
Non-ICU hospitalization, not requiring SO	50	42		
Non-ICU hospitalization, requiring SO	18	25		
Admitted to the ICU, not requiring IMV	6	6		
Requiring invasive mechanical ventilation	2	3		
Death	3	0		

### Statistical analyses

Statistical analysis title	Statistical Analysis
Comparison groups	Placebo + SOC v Pimodivir + SOC

Number of subjects included in analysis	318
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.366
Method	Van Elteren test



## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

Up to 33 days

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

### Reporting groups

Reporting group title	Pimodivir + SOC
-----------------------	-----------------

Reporting group description: -

Reporting group title	Placebo+SOC
-----------------------	-------------

Reporting group description: -

Serious adverse events	Pimodivir + SOC	Placebo+SOC	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Pimodivir + SOC	Placebo+SOC	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No adverse events reported

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 March 2018	The overall reason was to implement the recommendations from specific Health Authorities.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The limited results for this early terminated trial are available in the attached CSR synopsis.

Notes: